{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:00:19Z","timestamp":1791907219211,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":688,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1186\/s13613-024-01384-1","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T02:02:02Z","timestamp":1727488922000},"page":"152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8255-0676","authenticated-orcid":false,"given":"Gennaro","family":"De Pascale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Lucio","family":"Cutuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Marinozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altea","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Sancho","family":"Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa Sofia","family":"Tanzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Luca","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikardo","family":"Xhemalaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cascarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella Maria Pia","family":"Ciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Sandroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1186\/s13613-024-01384-1_bb0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in Intensive Care Units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1186\/s13613-024-01384-1_bb0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"issue":"21","key":"10.1186\/s13613-024-01384-1_bb0020","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"issue":"8","key":"10.1186\/s13613-024-01384-1_bb0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.1995.03530080055041","article-title":"The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in Intensive Care (EPIC) study. EPIC International Advisory Committee","volume":"274","author":"Vincent","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.medin.2022.09.001","article-title":"Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae","volume":"47","author":"Lombardi","year":"2023","journal-title":"Med Intensiva (Engl Ed)"},{"issue":"4","key":"10.1186\/s13613-024-01384-1_bb0035","doi-asserted-by":"crossref","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. Baumannii ventilator-associated pneumonia: a propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"12","key":"10.1186\/s13613-024-01384-1_bb0040","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1186\/s13613-024-01384-1_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CPM.0000000000000098","article-title":"How to use Colistin in the ICU","volume":"22","author":"De Pascale","year":"2015","journal-title":"Clin Pulm Med"},{"issue":"9","key":"10.1186\/s13613-024-01384-1_bb0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-024-01384-1_bb0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorli","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1186\/s13613-024-01384-1_bb0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-024-01384-1_bb0065","doi-asserted-by":"crossref","unstructured":"Forrest A, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Li J et al. Pharmacokinetic\/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in critically ill patients. Antimicrob Agents Chemother. 2017;61(11).","DOI":"10.1128\/AAC.01367-17"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1186\/s13613-024-01384-1_bb0075","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-024-01384-1_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-024-01384-1_bb0085","doi-asserted-by":"crossref","unstructured":"Cutuli SL, Cascarano L, Lazzaro P, Tanzarella ES, Pintaudi G, Grieco DL et al. Antimicrobial exposure in critically ill patients with Sepsis-Associated Multi-organ Dysfunction requiring extracorporeal organ support: a narrative review. Microorganisms. 2023;11(2).","DOI":"10.3390\/microorganisms11020473"},{"issue":"4","key":"10.1186\/s13613-024-01384-1_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1186\/s13613-024-01384-1_bb0095","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"17","author":"Group","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"11","key":"10.1186\/s13613-024-01384-1_bb0100","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"issue":"23","key":"10.1186\/s13613-024-01384-1_bb0105","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Force","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1186\/s13613-024-01384-1_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1186\/s13613-024-01384-1_bb0115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1186\/s13613-024-01384-1_bb0120","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.01367-09","article-title":"Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Gobin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-024-01384-1_bb0125","doi-asserted-by":"crossref","unstructured":"De Pascale G, Pintaudi G, Lisi L, De Maio F, Cutuli SL, Tanzarella ES et al. Use of High-Dose Nebulized Colistimethate in patients with colistin-only susceptible Acinetobacter baumannii VAP: clinical, pharmacokinetic and Microbiome features. Antibiot (Basel). 2023;12(1).","DOI":"10.3390\/antibiotics12010125"},{"issue":"12","key":"10.1186\/s13613-024-01384-1_bb0130","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s40262-017-0561-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of Colistin","volume":"56","author":"Gregoire","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1186\/s13613-024-01384-1_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-024-01384-1_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/IJNRD.S42791","article-title":"Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration","volume":"6","author":"Honore","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"11","key":"10.1186\/s13613-024-01384-1_bb0145","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1128\/AAC.49.11.4814-4815.2005","article-title":"Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration","volume":"49","author":"Li","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0150","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.00985-12","article-title":"Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration","volume":"57","author":"Karvanen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1186\/s13613-024-01384-1_bb0155","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dks257","article-title":"Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study","volume":"67","author":"Markou","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-024-01384-1_bb0160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2016.06.008","article-title":"Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"48","author":"Karaiskos","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000484974","article-title":"Modified Colistin Regimen for critically ill patients with Acute Renal impairment and continuous renal replacement therapy","volume":"63","author":"Menna","year":"2018","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1186\/s13613-024-01384-1_bb0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40620-014-0143-3","article-title":"Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies","volume":"28","author":"Mariano","year":"2015","journal-title":"J Nephrol"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/AAC.03783-14","article-title":"Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration","volume":"59","author":"Akers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-024-01384-1_bb0180","doi-asserted-by":"crossref","unstructured":"Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin dosed as in normal renal function in patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2019;63(2).","DOI":"10.1128\/AAC.01957-18"},{"issue":"1","key":"10.1186\/s13613-024-01384-1_bb0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1378\/chest.10-2031","article-title":"Colistin use in critically ill patients: in search of the optimal dosing","volume":"139","author":"De Pascale","year":"2011","journal-title":"Chest"},{"issue":"6","key":"10.1186\/s13613-024-01384-1_bb0190","doi-asserted-by":"crossref","first-page":"106588","DOI":"10.1016\/j.ijantimicag.2022.106588","article-title":"Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia","volume":"59","author":"Gkoufa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1186\/s13613-024-01384-1_bb0195","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-024-01384-1_bb0200","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1212\/WNL.0000000000010280","article-title":"Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit","volume":"95","author":"Madia","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"10.1186\/s13613-024-01384-1_bb0205","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/ene.14444","article-title":"Assessment of neurological manifestations in hospitalized patients with COVID-19","volume":"27","author":"Luigetti","year":"2020","journal-title":"Eur J Neurol"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-024-01384-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:57:27Z","timestamp":1776671847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025003000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2110582025003000"],"URL":"https:\/\/doi.org\/10.1186\/s13613-024-01384-1","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-024-01384-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 The Author(s) 2024. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"152"}}